Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024)

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	JOKUBAITIS Vilija G ALROUGHANI Raed ALTINTAS Ayse EICHAU Sara HUGHES Stella WILLEKENS Barbara HORAKOVA Dana HAVRDOVA Eva Kubala OZAKBAS Serkan BOZ Cavit HABEK Mario KALINCIK Tomas ROOS Izanne ETEMADIFAR Masoud PETERKA Marek LECHNER-SCOTT Jeannette MECA-LALLANA Jose E ROUS Zuzana HOUSKOVA Jana PRAT Alexandre GIRARD Marc AMPAPA Radek BUZZARD Katherine SKIBINA Olga JOHN Nevin A KERMODE Allan G FABIS-PEDRINI Marzena J FOSCHI Matteo SURCINELLI Andrea BLANCO Yolanda BAGHBANIAN Seyed Mohammad GERLACH Oliver MACDONELL Richard PAVELEK Zbysek ŠTOURAČ Pavel MCCOMBE Pamela LAUREYS Guy BUTZKUEVEN Helmut ANNEKE van der Walt GRAY Orla
Year of publication	2025
Type	Article in Periodical
Magazine / Source	MULTIPLE SCLEROSIS JOURNAL
MU Faculty or unit	Faculty of Medicine
Citation
web	https://journals.sagepub.com/doi/10.1177/13524585251349125
Doi	https://doi.org/10.1177/13524585251349125
Keywords	Multiple sclerosis; neuromyelitis optica spectrum disorder; pregnancy; disease-modifying therapy; neonatal outcomes
Attached files	Four_years_on_Pregnancy_and_birth_outcomes_reported_in_the_MSBase_pregnancy__neonatal_outcomes__and_Women_s_Health_Registry__2020-2024_.pdf
Description	Background: Family planning is an important aspect of multiple sclerosis (MS), and neuromyelitis optica spectrum disorder (NMOSD) management. Knowledge gaps remain, including optimal perinatal management strategies, and fetal risks associated with disease-modifying therapy (DMT) exposure.Objective: To describe perinatal DMT use, together with pregnancy and neonatal outcomes prospectively recorded in the International MSBase Pregnancy and Women's Health Registry.Methods: We report summary statistics for data collected between May 2020 and August 2024.Results: A total of 1887 relapsing-remitting MS (RRMS), 12 primary-progressive MS (PPMS), 2 radiologically isolated syndrome (RIS) and 21 NMOSD completed pregnancies were recorded, including 1644 (85.5%) live births, 208 (10.8%) miscarriages, and 6 (0.3%) neonatal deaths. Most women had unassisted (53.8%) or assisted (7.4%) vaginal births. Seventy five percent of pregnancies had DMT exposures within 6 months preconception; 19% of NMOSD, and 62% of MS pregnancies were DMT-exposed during gestation; 18.1% of pregnancies reported in-pregnancy monoclonal antibody DMT exposure. No overt safety signals were seen.Conclusion: This first report from the newly launched MSBase pregnancy registry, establishes an increasing number of pregnancies being conceived on monoclonal antibody therapies. Although no safety signals were observed, it is important to continue monitoring for safety signals in real-world databases as the use of highly effective therapies continues to increase perinatally.
Related projects:	Národní ústav pro neurologický výzkum